Stoke Therapeutics Inc. (STOK): Price and Financial Metrics
STOK Price/Volume Stats
| Current price | $11.68 | 52-week high | $17.58 |
| Prev. close | $11.30 | 52-week low | $4.09 |
| Day low | $10.81 | Volume | 1,183,000 |
| Day high | $11.84 | Avg. volume | 744,717 |
| 50-day MA | $12.48 | Dividend yield | N/A |
| 200-day MA | $12.96 | Market Cap | 618.65M |
STOK Stock Price Chart Interactive Chart >
Stoke Therapeutics Inc. (STOK) Company Bio
Stoke Therapeutics, Inc. was founded in 2014 by Professor Adrian Krainer, PhD. and Isabel Aznarez, PhD to research and develop treatments for the underlying cause of genetic diseases. The company focuses on developing antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver, and kidney. Stoke’s proprietary platform, Targeted Augmentation of Nuclear Gene Output (TANGO) allows for the delivery of disease-modifying therapies in a precise and controlled manner. Edward M. Kaye, M.D., currently serves as the company’s director and Chief Executive Officer.
STOK Price Returns
| 1-mo | 3.64% |
| 3-mo | -15.05% |
| 6-mo | -18.49% |
| 1-year | 119.14% |
| 3-year | -43.08% |
| 5-year | -56.53% |
| YTD | 122.05% |
| 2023 | -43.01% |
| 2022 | -61.53% |
| 2021 | -61.26% |
| 2020 | 118.68% |
| 2019 | N/A |
Loading social stream, please wait...